Balaji Amines Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹468 Cr +37.2% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
BA

Balaji Amines Ltd

Q3 FY26Chemicals & Petrochemicals

Balaji Amines Q3 FY26: Revenue ₹331.30 Cr, PAT ₹30.76 Cr

Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹331Cr
+5.8% YoY
−2.9% QoQ
Net profit
₹31Cr
0% YoY
−16.2% QoQ
Margin
17%
+2 pp YoY
−1 pp QoQ

Based on Balaji Amines Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹2,226
Market cap₹7.0K Cr
P/E34.5

The short version

Revenue from Operations for Q3FY26: ₹331.30 crore, compared to ₹320.59 crore in Q3FY25 (consolidated) and ₹304.68 crore in Q3FY25 (standalone). EBITDA for Q3FY26 (Consolidated): ₹61.67 crore, up 15.12% YoY from ₹53.57 crore in Q3FY25

From Balaji Amines Ltd's Q3 FY26 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Revenue from Operations for Q3FY26: ₹331.30 crore, compared to ₹320.59 crore in Q3FY25 (consolidated) and ₹304.68 crore in Q3FY25 (standalone).
  • Consolidated Q3FY26 Revenue growth YoY: 4.90%.
  • Standalone Q3FY26 Revenue growth YoY: 0.62%.
  • Total volumes for Q3FY26: 25,894 MT vs. 24,097 MT in Q3FY25.
  • Amines volumes Q3FY26: 6,993 MT.
  • Amines Derivatives volumes Q3FY26: 9,223 MT.
  • Specialty Chemicals volumes Q3FY26: 9,678 MT.

2 more points from Balaji Amines Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Balaji Amines Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Unit 4 Greenfield Capex Phases 2 & 3 to be completed by FY 2027, including increased capacity utilization.
  • Dimethyl Ether (DME) plant of 100,000 TPA capacity under Phase 3 expansion; under erection; commissioning expected FY 2026-27.
  • N-Methyl Morpholine (NMM) 5,000 TPA manufacturing facility under execution; commissioning expected FY 2026-27.
  • PG Pharma Grade facility under execution; commissioning expected FY 2026-27.
  • Acetonitrile (ACN) improved process plant under execution; commissioning expected FY 2026-27.
  • Methylamines capacity expanded from 48,000 TPA to 88,000 TPA; latest tech plant commissioned Nov 10, 2024.

2 more points from Balaji Amines Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Balaji Amines Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Balaji Amines Ltd said on order book & pipeline — free account, 30 seconds.

Balaji Amines Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Balaji Amines Ltd Q3 FY26 results — key figures

Balaji Amines Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue331313+5.8%341-2.9%
Operating profit (EBITDA)5746+23.9%60-5%
Operating margin17%15%+2 pp18%-1 pp
Profit before tax4641+12.2%52-11.5%
Net profit (PAT)31310%37-16.2%
EPS (₹)9.7010.24-5.3%10.67-9.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹468 Cr, net profit ₹67 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Neochem Bio (Q3 FY26)

    Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and

  • Thirumalai Chemicals (Q3 FY26)

    Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran

  • IVP (Q3 FY26)

    Q3 FY26 Revenue from Operations: ₹144.97 crore . Key investor presentation takeaways from IVP's Q3 FY26 investor presentation — and how it ranks against sector

  • Gujarat Alkalies (Q3 FY26)

    3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Balaji Amines Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Balaji Amines Ltd Q3 FY26 results?

Revenue from Operations for Q3FY26: ₹331.30 crore, compared to ₹320.59 crore in Q3FY25 (consolidated) and ₹304.68 crore in Q3FY25 (standalone). EBITDA for Q3FY26 (Consolidated): ₹61.67 crore, up 15.12% YoY from ₹53.57 crore in Q3FY25

What is Balaji Amines Ltd share price analysis?

Balaji Amines Ltd currently shows a neutral. The stock trades at a P/E of 34.5 with a market cap of ₹7,036 Cr. Investors should review the full earnings analysis for detailed insights.

Is Balaji Amines Ltd planning capital expenditure?

Unit 4 Greenfield Capex Phases 2 & 3 to be completed by FY 2027, including increased capacity utilization.

Keep Balaji Amines Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.